MA37949B1 - Polypeptides contenant fc ayant une glycosylation modifiée et une fonction effectrice réduite - Google Patents

Polypeptides contenant fc ayant une glycosylation modifiée et une fonction effectrice réduite

Info

Publication number
MA37949B1
MA37949B1 MA37949A MA37949A MA37949B1 MA 37949 B1 MA37949 B1 MA 37949B1 MA 37949 A MA37949 A MA 37949A MA 37949 A MA37949 A MA 37949A MA 37949 B1 MA37949 B1 MA 37949B1
Authority
MA
Morocco
Prior art keywords
binding polypeptides
effector function
reduced effector
modified glycosylation
antigen
Prior art date
Application number
MA37949A
Other languages
English (en)
Other versions
MA37949A1 (fr
Inventor
Clark Pan
Huawei Qiu
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50278674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37949(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2012/003819 external-priority patent/WO2013037484A2/fr
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MA37949A1 publication Critical patent/MA37949A1/fr
Publication of MA37949B1 publication Critical patent/MA37949B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des polypeptides de liaison (par exemple des anticorps) et des conjugués médicamenteux de ceux-ci, comportant un domaine fc ayant un profil de glycosylation modifié et une fonction effectrice réduite. Dans un mode de réalisation particulier, le domaine fc comporte : un résidu asparagine à la position d'acide aminé 298, selon la numération eu; un résidu sérine ou thréonine à la position d'acide aminé 300, selon la numération eu. L'invention concerne également des acides nucléiques codant pour les polypeptides de liaison à un antigène, des vecteurs d'expression recombinants et des cellules hôtes pour la fabrication de tels polypeptides de liaison à un antigène. L'invention concerne également des procédés d'utilisation des polypeptides de liaison à un antigène selon la présente invention pour traiter une maladie.
MA37949A 2012-09-12 2013-09-12 Polypeptides contenant fc ayant une glycosylation modifiée et une fonction effectrice réduite MA37949B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2012/003819 WO2013037484A2 (fr) 2011-09-12 2012-09-12 Anticorps anti-alphabêtatcr
US201361776715P 2013-03-11 2013-03-11
PCT/US2013/059481 WO2014043361A1 (fr) 2012-09-12 2013-09-12 Polypeptides contenant fc ayant une glycosylation modifiée et une fonction effectrice réduite

Publications (2)

Publication Number Publication Date
MA37949A1 MA37949A1 (fr) 2016-05-31
MA37949B1 true MA37949B1 (fr) 2017-07-31

Family

ID=50278674

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37949A MA37949B1 (fr) 2012-09-12 2013-09-12 Polypeptides contenant fc ayant une glycosylation modifiée et une fonction effectrice réduite

Country Status (35)

Country Link
EP (3) EP2895513B1 (fr)
JP (1) JP6438397B2 (fr)
KR (3) KR102185151B1 (fr)
CN (2) CN110590953A (fr)
AU (1) AU2013315499B2 (fr)
CA (1) CA2884762C (fr)
CL (1) CL2015000606A1 (fr)
CR (1) CR20150147A (fr)
CY (1) CY1120909T1 (fr)
DK (2) DK3366705T5 (fr)
DO (1) DOP2015000050A (fr)
EA (2) EA202091166A1 (fr)
EC (1) ECSP15014133A (fr)
ES (2) ES2684549T3 (fr)
FI (1) FI3366705T3 (fr)
HK (1) HK1207389A1 (fr)
HR (2) HRP20230623T1 (fr)
HU (2) HUE039337T2 (fr)
IL (4) IL237640B (fr)
LT (2) LT2895513T (fr)
MA (1) MA37949B1 (fr)
MX (2) MX366103B (fr)
MY (1) MY170126A (fr)
NZ (1) NZ705983A (fr)
PE (1) PE20150650A1 (fr)
PH (1) PH12015500528A1 (fr)
PL (2) PL3366705T3 (fr)
PT (2) PT2895513T (fr)
RS (2) RS57748B1 (fr)
SG (2) SG10201701831VA (fr)
SI (2) SI2895513T1 (fr)
TN (1) TN2015000085A1 (fr)
UA (1) UA116995C2 (fr)
WO (1) WO2014043361A1 (fr)
ZA (1) ZA201501417B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
SG11201506088RA (en) 2013-03-11 2015-09-29 Genzyme Corp Hyperglycosylated binding polypeptides
HUE061339T2 (hu) 2014-03-19 2023-06-28 Genzyme Corp Targetáló csoportok helyspecifikus glikotechnikai átalakítása
EP3129402A4 (fr) 2014-04-08 2017-12-13 University Of Georgia Research Foundation, Inc. Glycoconjugués anticorps-médicament spécifiques d'un site et procédés
RU2728235C2 (ru) * 2014-06-12 2020-07-28 СиЭсПиСи ДОФЕН КОРПОРЕЙШН Конъюгат антитела и лекарственного средства, композиции на его основе и способы их получения
AU2015330869B2 (en) 2014-10-09 2021-07-08 Genzyme Corporation Glycoengineered antibody drug conjugates
TWI824372B (zh) 2015-10-12 2023-12-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
EP3222292A1 (fr) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Conjugués d'amanitine
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
CN110167965A (zh) 2016-11-08 2019-08-23 瑞泽恩制药公司 拮抗瘦素受体的抗原结合蛋白
WO2018107116A1 (fr) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Procédés de réduction de la toxicité de conjugués anticorps-médicament, et compositions produites par ceux-ci
GB201717446D0 (en) 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
US11834500B2 (en) 2017-12-18 2023-12-05 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof
KR20200141461A (ko) 2018-04-06 2020-12-18 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체 작용제 항체를 사용한 치료 방법
JP1640846S (fr) * 2018-10-16 2019-09-09
US12024556B2 (en) 2018-11-21 2024-07-02 Regeneron Pharmaceuticals, Inc. Anti-Staphylococcus antibodies and uses thereof
WO2020132483A1 (fr) 2018-12-21 2020-06-25 Regeneron Pharmaceuticals, Inc. Analogues de rifamycine et conjugués anticorps-médicament de ceux-ci
SG11202107272SA (en) 2019-02-01 2021-07-29 Regeneron Pharma Anti-il2 receptor gamma antigen-binding proteins
CA3131705A1 (fr) * 2019-03-27 2020-10-01 Umc Utrecht Holding B.V. Anticorps iga modifies et procedes d'utilisation
WO2021226444A2 (fr) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Pièges et mini-pièges de vegf et procédés de traitement de troubles oculaires et de cancers
AU2021343444A1 (en) 2020-09-15 2023-04-20 Regeneron Pharmaceuticals, Inc. Use of lepr agonists for pain
KR20220052098A (ko) 2020-10-20 2022-04-27 주식회사 엘지에너지솔루션 마스킹 테이프를 이용한 전극 시편에 대한 물성 측정 시스템 및 이를 이용한 물성 측정 방법
KR102576252B1 (ko) * 2021-04-07 2023-09-11 아주대학교산학협력단 산화된 면역글로불린을 유효성분으로 포함하는 면역조절 기능 이상 관련 질환 예방 또는 치료용 약학적 조성물
TW202325273A (zh) * 2021-10-22 2023-07-01 美商杜夫特學院信託管理公司 靶向fap之中子捕獲劑及與其相關之用途及調配物
WO2024026474A1 (fr) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions et méthodes d'administration médiée par le récepteur de la transferrine (tfr) au cerveau et au muscle
WO2024026494A1 (fr) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Particules virales reciblées vers le récepteur 1 de transferrine
US20240052051A1 (en) 2022-07-29 2024-02-15 Regeneron Pharmaceuticals, Inc. Anti-tfr:payload fusions and methods of use thereof
WO2024098002A1 (fr) 2022-11-04 2024-05-10 Regeneron Pharmaceuticals, Inc. Protéines de liaison de sous-unité auxiliaire gamma 1 du canal calcique dépendant de la tension (cacng1) et administration médiée par cacng1 au muscle squelettique
US20240158515A1 (en) 2022-11-14 2024-05-16 Regeneron Pharmaceuticals, Inc. Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof
WO2024107765A2 (fr) 2022-11-14 2024-05-23 Regeneron Pharmaceuticals, Inc. Compositions et procédés d'administration médiée par le récepteur 3 du facteur de croissance des fibroblastes à des astrocytes

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
EP0627932B1 (fr) 1992-11-04 2002-05-08 City Of Hope Structure d'anticorps
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
DE69738522T2 (de) 1996-08-02 2009-04-02 Bristol-Myers Squibb Co. Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (fr) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Récepteurs Fc recombinantes et solubles
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR20060067983A (ko) 1999-01-15 2006-06-20 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
WO2002002781A1 (fr) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Proteines de fusion heterodimeres
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
ATE489395T1 (de) 2000-12-12 2010-12-15 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003209446B2 (en) 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
EP3502133A1 (fr) 2002-09-27 2019-06-26 Xencor, Inc. Variantes fc optimisées et leurs procédés de génération
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2368578A1 (fr) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification et ingénierie d'anticorps avec régions FC de variante et procédés d'utilisation associés
JP4629047B2 (ja) * 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
US8399618B2 (en) * 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
CA2545603A1 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
CN1918178B (zh) 2004-01-12 2012-08-22 应用分子进化公司 Fc区变体
EP1737890A2 (fr) 2004-03-24 2007-01-03 Xencor, Inc. Variantes d'immunoglobuline a l'exterieur de la region fc
WO2005123780A2 (fr) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese
WO2006085967A2 (fr) 2004-07-09 2006-08-17 Xencor, Inc. Anticorps monoclonaux optimises anti-cd20 a variants fc
EP2471813B1 (fr) 2004-07-15 2014-12-31 Xencor, Inc. Variantes optimisées de Fc
AU2005289594B2 (en) * 2004-09-27 2012-02-02 Centocor, Inc. Srage mimetibody, compositions, methods and uses
WO2006047350A2 (fr) 2004-10-21 2006-05-04 Xencor, Inc. Variants d'immunoglobuline igg a fonction effectrice optimisee
JP2008537941A (ja) * 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
EP1888649A2 (fr) * 2005-05-09 2008-02-20 GlycArt Biotechnology AG Molecules de liaison a l'antigene possedant des zones fc modifiees et une liaison alteree aux recepteurs fc
WO2006130834A2 (fr) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System Molecules d'immunoglobuline ayant des proprietes ameliorees
SG163548A1 (en) 2005-06-30 2010-08-30 Centocor Inc Methods and compositions with enhanced therapeutic activity
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8460362B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
JP5357778B2 (ja) * 2007-01-23 2013-12-04 ゼンコー・インコーポレイテッド 最適化ｃｄ４０抗体および前記を使用する方法
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
US20110137011A1 (en) * 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
MX352889B (es) * 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
TWI838039B (zh) 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
UY34317A (es) * 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß

Also Published As

Publication number Publication date
MY170126A (en) 2019-07-05
CN104797601A (zh) 2015-07-22
PT2895513T (pt) 2018-10-08
EP3366705A1 (fr) 2018-08-29
IL271027B (en) 2020-09-30
EA035987B1 (ru) 2020-09-09
FI3366705T3 (fi) 2023-07-28
MX2019007753A (es) 2019-09-09
HUE062876T2 (hu) 2023-12-28
IL286766A (en) 2021-10-31
IL276866B (en) 2021-10-31
RS57748B1 (sr) 2018-12-31
JP6438397B2 (ja) 2018-12-12
SI2895513T1 (sl) 2018-11-30
RS64317B1 (sr) 2023-08-31
DK2895513T3 (en) 2018-09-03
ES2950509T3 (es) 2023-10-10
MA37949A1 (fr) 2016-05-31
EA201590545A1 (ru) 2015-08-31
CA2884762C (fr) 2022-07-19
PT3366705T (pt) 2023-07-19
SI3366705T1 (sl) 2023-08-31
ECSP15014133A (es) 2017-02-24
HRP20181354T1 (hr) 2018-10-19
TN2015000085A1 (en) 2016-06-29
DOP2015000050A (es) 2015-04-15
EA202091166A1 (ru) 2021-04-30
CN110590953A (zh) 2019-12-20
HUE039337T2 (hu) 2018-12-28
MX2015003234A (es) 2015-11-16
AU2013315499A1 (en) 2015-04-02
KR102426488B1 (ko) 2022-07-28
KR102185151B1 (ko) 2020-12-01
CY1120909T1 (el) 2019-12-11
AU2013315499B2 (en) 2018-08-09
MX366103B (es) 2019-06-27
NZ705983A (en) 2018-06-29
IL276866A (en) 2020-10-29
PL2895513T3 (pl) 2018-11-30
CL2015000606A1 (es) 2015-11-13
KR20200136044A (ko) 2020-12-04
PE20150650A1 (es) 2015-05-26
LT3366705T (lt) 2023-07-25
ES2684549T3 (es) 2018-10-03
HRP20230623T1 (hr) 2023-09-29
EP3366705B1 (fr) 2023-05-03
KR20150054931A (ko) 2015-05-20
SG11201501521TA (en) 2015-03-30
EP4223783A2 (fr) 2023-08-09
IL271027A (en) 2020-01-30
DK3366705T5 (da) 2024-09-30
PH12015500528A1 (en) 2015-05-04
KR20220110855A (ko) 2022-08-09
SG10201701831VA (en) 2017-05-30
ZA201501417B (en) 2016-12-21
EP2895513A1 (fr) 2015-07-22
IL237640B (en) 2019-12-31
CR20150147A (es) 2015-05-29
CA2884762A1 (fr) 2014-03-20
BR112015005352A2 (pt) 2017-08-08
EP4223783A3 (fr) 2023-11-15
WO2014043361A1 (fr) 2014-03-20
EP2895513B1 (fr) 2018-05-23
PL3366705T3 (pl) 2023-09-18
IL237640A0 (en) 2015-04-30
JP2015533490A (ja) 2015-11-26
LT2895513T (lt) 2018-09-10
DK3366705T3 (da) 2023-07-31
CN104797601B (zh) 2019-08-30
HK1207389A1 (en) 2016-01-29
UA116995C2 (uk) 2018-06-11

Similar Documents

Publication Publication Date Title
MA37949A1 (fr) Polypeptides contenant fc ayant une glycosylation modifiée et une fonction effectrice réduite
Osbourn et al. HpARI protein secreted by a helminth parasite suppresses interleukin-33
Besche et al. Isolation of mammalian 26S proteasomes and p97/VCP complexes using the ubiquitin-like domain from HHR23B reveals novel proteasome-associated proteins
Chaparro-Riggers et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9
Rozek et al. Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment
MA34738B1 (fr) Neutralisation d'anticorps anti-ccl20
EA201270214A1 (ru) Способы очистки рекомбинантного adamts13 и других белков и их композиции
MA40309A1 (fr) Anticorps anti-cd73 et leurs utilisations
EA200970231A1 (ru) СПОСОБ ОЧИСТКИ Fc-СОДЕРЖАЩИХ БЕЛКОВ
EA200700751A1 (ru) Способы и композиции для улучшения продуцирования рекомбинантного белка
WO2010057203A3 (fr) Particules de hdl pour administration d'acides nucléiques
MA41759A (fr) Inclusion de l'exon 2, induite par antisens, dans une alpha-glucosidase acide
MA35345B1 (fr) Proteines de liaisons a un antigene ayant une liaison accrue a fcrn
MA34527B1 (fr) Anticorps contre la metalloproteinase de matrice 9
MA34605B1 (fr) Mutants beta vulgaris tolerents a un herbicide inhibiteurs d'als
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
WO2007133623A3 (fr) Agent de diagnostic peptidique pour la maladie de lyme
Manconi et al. Salivary cystatins: exploring new post-translational modifications and polymorphisms by top-down high-resolution mass spectrometry
MA34475B1 (fr) Peptide ou complexe de peptide se liant a l'integrine a2 et procedes et utilisation mettant en oeuvre ceux-ci
WO2010065407A3 (fr) Anticorps de lamproie recombinés d'affinité élevée sélectionnés au moyen d'une plate-forme de présentation en surface de levure
Simó et al. Performance of combinatorial peptide libraries in capturing the low-abundance proteome of red blood cells. 1. Behavior of mono-to hexapeptides
WO2022115715A1 (fr) Compositions et procédés d'épuisement sélectif de molécules cibles
FR3044312B1 (fr) Polypeptides mutes de hev et leur utilisation pour le dosage d'anticorps anti-hev
Sfera et al. Long COVID as a tauopathy: of “Brain Fog” and “Fusogen Storms”
WO2013138259A3 (fr) Polypeptides pour le traitement et/ou la limitation d'une infection par la grippe